OPPIDUM surveillance program: 20 years of information on drug abuse in France

Fundamental and Clinical Pharmacology

Volumn 27, Issue 6, 2013, Pages 672-682

  Frauger, Elisabeth ^a,b   Moracchini, Christophe ^a,b   Le Boisselier, Reynald ^c   Braunstein, David ^a   Thirion, Xavier ^b   Micallef, Joëlle ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Pharmacoepidemiology; Postmarketing surveillance system; Prescription drug abuse; Substance related disorders

Indexed keywords

ALPRAZOLAM; BROMAZEPAM; BUPRENORPHINE; CLONAZEPAM; CLORAZEPATE DIPOTASSIUM; DIAMORPHINE; DIAZEPAM; FLUNITRAZEPAM; ILLICIT DRUG; METHYLPHENIDATE; OPIATE; OXAZEPAM; PRAZEPAM; PRESCRIPTION DRUG; ZOLPIDEM; ZOPICLONE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; DRUG ABUSE; DRUG DEPENDENCE; DRUG MISUSE; DRUG SURVEILLANCE PROGRAM; FRANCE; HEALTH CARE POLICY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; OBSERVATION OF ILLEGAL DRUGS AND MISUSE OF PSYCHOTROPIC MEDICATION SURVEILLANCE PROGRAM; PRACTICE GUIDELINE; PRIORITY JOURNAL;

PHARMACOEPIDEMIOLOGY; POSTMARKETING SURVEILLANCE SYSTEM; PRESCRIPTION DRUG ABUSE; SUBSTANCE-RELATED DISORDERS;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HUMANS; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; PSYCHOTROPIC DRUGS; STREET DRUGS; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS;

EID: 84886597455     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12024     Document Type: Article

References (57)

1. Schneider M.F., Bailey J.E., Cicero T.J. et al. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007. Pharmacoepidemiol. Drug Saf. (2009) 18 778-790.
2. Hernandez S.H., Nelson L.S. Prescription drug abuse: insight into the epidemic. Clin. Pharmacol. Ther. (2010) 88 307-317.
3. Ghandour L.A., El Sayed D.S., Martins S.S. Prevalence and patterns of commonly abused psychoactive prescription drugs in a sample of university students from Lebanon: an opportunity for cross-cultural comparisons. Drug Alcohol Depend. (2012) 121 110-117.
4. Balster R.L., Bigelow G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. (2003) 70 S13-S40.
5. Carter L.P., Griffiths R.R. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend. (2009) 105 S14-S25.
6. Griffiths R.R., Bigelow G.E., Ator N.A. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. (2003) 70 S41-S54.
7. Food and Drug Administration. Guidance for Industry Assessment of Abuse Potential of Drugs. 2010 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf (Accessed on 06 May 2012)
8. Gerada C., Ashworth M. ABC of mental health. Addiction and dependence-I: Illicit drugs. BMJ (1997) 315 297-300.
9. Schuster C.R., Barthwell A.G., Henningfield J.E. Introduction to College on Problems of Drug Dependence special conference on risk management and post-marketing surveillance of CNS drugs. Drug Alcohol Depend. (2009) 105 S4-S8.
10. Dart R.C. Monitoring risk: post marketing surveillance and signal detection. Drug Alcohol Depend. (2009) 105 S26-S32.
11. Nordmann S., Frauger E., Pauly V. et al. Post-marketing surveillance systems for psychoactive prescription drug abuse. Therapie (2011) 66 263-272.
12. Grucza R.A., Abbacchi A.M., Przybeck T.R., Gfroerer J.C. Discrepancies in estimates of prevalence and correlates of substance use and disorders between two national surveys. Addiction (2007) 102 623-629.
13. Bachman J.G., O'Malley P.M., Johnston L.D., Schulenberg J.E., Wallace J.M. Jr. Racial/ethnic differences in the relationship between parental education and substance use among U.S. 8th-, 10th-, and 12th-grade students: findings from the Monitoring the Future project. J. Stud. Alcohol Drugs (2011) 72 279-285.
14. Terry-McElrath Y.M., O'Malley P.M., Johnston L.D. Reasons for Drug Use among American Youth by Consumption Level, Gender, and Race/Ethnicity: 1976-2005. J. Drug Issues. (2009) 39 677-714.
15. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS). Highlights - 2007. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-45, DHHS Publication No. (SMA) 09-4360, Rockville, MD, 2009. http://wwwdasis.samhsa.gov/teds07/tedshigh2k7.pdf (Accessed on 06 May 2012).
16. Micaleff J., Jolliet P., Victorri-Vigneau C. et al. First meeting of the French CEIP (centres d'évaluation et d'information sur la pharmacodépendance). Assessment of the abuse and pharmacodependence potential during drug development. Therapie (2008) 63 55-65.
17. Thirion X., Micallef J., Barrau K. et al. Recent evolution in opiate dependence in France during generalisation of maintenance treatments. Drug Alcohol Depend. (2001) 61 281-285.
18. Frauger E., Nordmann S., Orleans V. et al. Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey. Fundam. Clin. Pharmacol. (2011) 26 549-556.
19. San Marco J.L., Jouglard J., Auquier P. et al. A surveillance method for products used by drug addicts examined in emergency units. Therapie (1993) 48 609-616.
20. San Marco J.L., Jouglard J., Thirion X. et al. Observation of illicit or misused psychotropic drugs (O.P.P.I.D.U.M.): five years of surveillance of products consumed by drug addicts at Marseille. Therapie (1996) 51 586-598.
21. Thirion X., Micallef J., Guet F. et al. Dependence on psychotropic drugs and substitution treatment: recent trends. The OPPIDUM study of the Centers for Evaluation and Information on Drug Dependence (CEIP), October 1997. Therapie (1999) 54 243-249.
22. Thirion X., Micallef J., Barrau K., Djezzar S., Sanmarco J.L., Lagier G. Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme. Eur. Addict. Res. (2001) 7 32-36.
23. Barrau K., Thirion X., Micallef J., Chuniaud-Louche C., Bellemin B. San Marco J.L. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction (2001) 96 1433-1441.
24. Bernard N., Bellemin B., Thirion X., Chuniaud-Louche C., Descotes J. OPPIDUM, a tool for assessing the local misuse of psychotropic drugs? Therapie (2002) 57 198-201.
25. Armand C., Thirion X., Saillard C., Lapeyre-Mestre M., Lambert H. Neocodion misuse: evolution between 1992 and 2002. Therapie (2004) 59 547-553.
26. Modelon H., Frauger E., Laurenceau D. et al. Psychotropic drug addiction: consumption study of specific population by the survey OPPIDUM 2004 from the CEIP network. Therapie (2007) 62 337-346.
27. Frauger E., Vigneau C., Orléans V. et al. Consumption of cannabis among subjects with history of abuse/dependence or under an opiate maintenance therapy: OPPIDUM data in 2006 and main trends since 2004. Therapie (2008) 63 119-127.
28. Pauly V., Frauger E., Rouby F. et al. Analysis of addictive behaviours among new prisoners in France using the OPPIDUM program. Encephale (2010) 36 122-131.
29. Fatseas M., Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr. Psychiatry Rep. (2007) 9 358-364.
30. Auriacombe M., Fatséas M., Dubernet J., Daulouède J.P., Tignol J. French field experience with buprenorphine. Am. J. Addict. (2004) 13(Suppl 1) S17-S28.
31. Nordmann S., Frauger E., Orleans V., Thirion X., Micallef J., and the CEIP network. Comparison of Methadone and High Dosage Buprenorphine Use in 2007 using the OPPIDUM Data. Le Courrier des Addictions (2009) 11 16-18.
32. Nordmann S., Frauger E., Pauly V. et al. Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey. Pharmacoepidemiol. Drug Saf. (2012) 21 184-190.
33. Djezzar S., Questel F., Burin E., Dally S. French Network of Centers for Evaluation and Information on Pharmacodependence. Chemical submission: results of 4-year French inquiry. Int. J. Legal Med. (2009) 123 213-219.
34. Ministère de la santé. Arrêté du 1er février 2001 relatif à la durée de prescription et au fractionnement de la délivrance des médicaments à base de flunitrazépam administrés par voie orale. Available at: http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000769439&dateTexte (Accessed on May 2012, 06).
35. Frauger E., Pauly V., Pradel V. et al. Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network. Fundam. Clin. Pharmacol. (2011) 25 633-641.
36. Nordmann S., Pradel V., Lapeyre-Mestre M. et al. Doctor shopping reveals geographical variations in opioid abuse. Pain Physician (2013) 16 89-100.
37. Brownstein J.S., Green T.C., Cassidy T.A., Butler S.F. Geographic information systems and pharmacoepidemiology: using spatial cluster detection to monitor local patterns of prescription opioid abuse. Pharmacoepidemiol. Drug Saf. (2010) 19 627-637.
38. Kaye S., Darke S. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction (2012) 107 467-477.
39. Frauger E., Spadari M., Djezzar S. et al. Study on intravenous use of methylphenidate and patterns on its abuse and diversion in two French administrative Areas (PACA, Corse). (Abstract). Fundam. Clin. Pharmacol. (2012) 26 72. [P215].
40. Frauger E., Spadari M., Djezzar S. et al. Étude des pratiques d'injection intraveineuse et autres détournements du méthylphénidate (région Paca-Corse). Le Courrier des Addictions. (2011) 4 15-20.
41. Dasgupta N., Schnoll S.H. Signal detection in post-marketing surveillance for controlled substances. Drug Alcohol Depend. (2009) 105 S33-S41.
42. Frauger E., Djezzar S., Giovannini B. et al. Signal detection of abuse in post-marketing surveillance in a specific geographical area: about methylphenidate. (Abstract). Fundam. Clin. Pharmacol. (2011) 25(Suppl 1) 59. [A301].
43. Cicero T.J., Inciardi J.A. Potential for abuse of buprenorphine in office-based treatment of opioid dependence. N. Engl. J. Med. (2005) 353 1863-1865.
44. Cicero T.J., Inciardi J.A., Adams E.H. et al. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol. Drug Saf. (2005) 14 851-859.
45. AFSSAPS. Data available on Risk management plan of High Dosage Buprenorphine. AFSSAPS, Saint Denis. April 2011. Available at: http://www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels-de-sante/BUPRENORPHINE-MERCK-R-Mise-a-disposition-et-informations-importantes-sur-le-bon-usage/(language)/fre-FR (Accessed on 6 May 2012).
46. AFSSAPS. Data available on Risk management plan of Methadone. AFSSAPS, Saint Denis; February 2011. Available at: http://www.afssaps.fr/var/afssaps_site/storage/original/application/1659c78c990453ba9fb649fb557cc7c8.pdf (Accessed on 06 May 2012).
47. Victorri-Vigneau C., Dailly E., Veyrac G., Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br. J. Clin. Pharmacol. (2007) 64 198-209.
48. Pauly V., Frauger E., Pradel V. et al. Monitoring of benzodiazepine diversion using a multi-indicator approach. Int. Clin. Psychopharmacol. (2011) 26 268-277.
49. AFSSAPS. Informations sur le bon usage du RIVOTRIL [Information on good use of RIVOTRIL. AFSSAPS, Saint Denis; July 2008. Available at: http://www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels-de-sante/Informations-importantes-sur-le-bon-usage-du-RIVOTRIL-R-et-sur-la-reduction-du-conditionnement-des-comprimes/(language)/fre-FR (Accessed on 6 May 2012).
50. Ministère de la santé et des sports. Arrêté du 12 octobre 2010 fixant la durée de prescription des médicaments contenant du clonazépam administrés par voie orale. Available at: http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000022927660&dateTexte=&categorieLien=id (Accessed on 6 May 2012).
51. Ministère de la santé. Arrêté du 24 août 2011 portant application de la réglementation des stupéfiants aux médicaments à base de clonazépam administrés par voie orale. Available at: http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000024535807&dateTexte=&categorieLien=id (Accessed on 6 May 2012).
52. Ministère de la santé, de la jeunesse, des sports et de la vie associative. Arrêté du 1er avril 2008 relatif à la liste de soins ou traitements susceptibles de faire l'objet de mésusage, d'un usage détourné ou abusif, pris en application de l'article L. 162-4-2 du code de la sécurité sociale. Available at: http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=D4E6857854925CD0754A976F18F8030B.tpdjo17v_1?cidTexte=JORFTEXT000018598614&dateTexte=&oldAction=rechJO&categorieLien=id (Accessed on 06 May 2012).
53. Harrison L. The validity of self-reported drug use in survey research: an overview and critique of research methods. NIDA Res. Monogr. (1997) 167 17-36.
54. Moracchini C., Orleans V., Miloudi S., Frauger E., Micallef J., Thirion X. General Practitioners' contribution to dependence assessment: the OPEMA programme. Thérapie (2012) 67 397-404. (article in French).
55. Boeuf O., Lapeyre-Mestre M. Survey of Forged Prescriptions to Investigate Risk of Psychoactive Medications Abuse in France: Results of OSIAP Survey. Drug Saf. (2007) 30 265-276.
56. Rouby F., Pradel V., Frauger E. et al. Assessment of abuse of tianeptine from a reimbursement database using 'doctor-shopping' as an indicator. Fundam. Clin. Pharmacol. (2012) 26 286-294.
57. Schneeweiss S., Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J. Clin. Epidemiol. (2005) 58 323-337.